scholarly journals OUTCOMES WITH BRUTON TYROSINE KINASE INHIBITION IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA AFTER PROGRESSION ON VENETOCLAX

2017 ◽  
Vol 35 ◽  
pp. 236-237
Author(s):  
M. Anderson ◽  
T.E. Lew ◽  
J.F. Seymour ◽  
A.W. Roberts ◽  
C. Tam
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Lymphocytic Leukemia ◽  
Small Lymphocytic Lymphoma ◽  
Kinase Inhibition ◽  
Tyrosine Kinase Inhibition ◽  
Bruton Tyrosine Kinase

scholarly journals Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

2016 ◽  
Vol 23 (14) ◽  
pp. 3734-3743 ◽  
Author(s):  
Viralkumar Patel ◽  
Kumudha Balakrishnan ◽  
Elena Bibikova ◽  
Mary Ayres ◽  
Michael J. Keating ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Lymphocytic Leukemia ◽  
Leukemia Cells ◽  
Bruton Tyrosine Kinase

scholarly journals Fulminant Acanthamoeba castellanii Encephalitis in an Ibrutinib-Treated Patient

2020 ◽  
Vol 7 (2) ◽  
Author(s):  
Jessica W Crothers ◽  
Liangge Hsu ◽  
Francisco M Marty
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Treated Patient ◽  
Fatal Outcome ◽  
Acanthamoeba Castellanii ◽  
Lymphocytic Leukemia ◽  
Immunologic Function ◽  
Bruton Tyrosine Kinase

Abstract We report a case of fulminant Acanthamoeba castellanii encephalitis in a patient with chronic lymphocytic leukemia treated with ibrutinib. The unusually rapid neurologic decline and fatal outcome observed are probably related to alterations in immunologic function associated with inhibition of Bruton tyrosine kinase.

Sign in / Sign up

Export Citation Format

Share Document